Serotonin 5-HT1A Receptors as Targets for Agents to Treat Psychiatric Disorders: Rationale and Current Status of Research
The DOI matches its Crossref record; 204 of the 205 references it cites were found in a registry or an index.
Abstract
Psychiatric disorders represent a large economic burden in modern societies. However, pharmacological treatments are still far from optimal. Drugs used in the treatment of major depressive disorder (MDD) and anxiety disorders (selective serotonin [5-HT] reuptake inhibitors [SSRIs] and serotonin-noradrenaline reuptake inhibitors [SNRIs]) are pharmacological refinements of first-generation tricyclic drugs, discovered by serendipity, and show low efficacy and slowness of onset. Moreover, antipsychotic drugs are partly effective in positive symptoms of schizophrenia, yet they poorly treat negative symptoms and cognitive deficits. The present article reviews the neurobiological basis of 5-HT1A receptor (5-HT1A-R) function and the role of pre- and postsynaptic 5-HT1A-Rs in the treatment of MDD, anxiety and psychotic disorders. The activation of postsynaptic 5-HT1A-Rs in corticolimbic areas appears beneficial for the therapeutic action of antidepressant drugs. However, presynaptic 5-HT1A-Rs play a detrimental role in MDD, since individuals with high density or function of presynaptic 5-HT1A-Rs are more susceptible to mood disorders and suicide, and respond poorly to antidepressant drugs. Moreover, the indirect activation of presynaptic 5-HT1A-Rs by SSRIs/SNRIs reduces 5-HT neuron activity and terminal 5-HT release, thus opposing the elevation of extracellular 5-HT produced by blockade of the serotonin transporter (SERT) in the forebrain. Chronic antidepressant treatment desensitizes presynaptic 5-HT1A-Rs, thus reducing the effectiveness of the 5-HT1A autoreceptor-mediated negative feedback. The prevention of this process by the non-selective partial agonist pindolol accelerates clinical antidepressant effects. Two new antidepressant drugs, vilazodone (marketed in the USA) and vortioxetine (in development) incorporate partial 5-HT1A-R agonist properties with SERT blockade. Several studies with transgenic mice have also established the respective role of pre- and postsynaptic 5-HT1A-Rs in MDD and anxiety. In agreement with pharmacological studies, presynaptic and postsynaptic 5-HT1A-R activation appears necessary for anxiolytic and antidepressant effects, respectively, yet, neurodevelopmental roles for 5-HT1A-Rs are also involved. Likewise, the use of small interference RNA has enabled the showing of robust antidepressant-like effects in mice after selective knock-down of 5-HT1A autoreceptors. Postsynaptic 5-HT1A-Rs in the prefrontal cortex (PFC) also appear important for the superior clinical effects of clozapine and other second-generation (atypical) antipsychotic drugs in the treatment of schizophrenia and related psychotic disorders. Despite showing a moderate in vitro affinity for 5-HT1A-Rs in binding assays, clozapine displays functional agonist properties at this receptor type in vivo. The stimulation of 5-HT1A-Rs in the PFC leads to the distal activation of the mesocortical pathway and to an increased dopamine release in PFC, an effect likely involved in the clinical actions of clozapine in negative symptoms and cognitive deficits in schizophrenia. The anxiolytic/antidepressant properties of 5-HT1A-R agonists in preclinical tests raised expectations enormously. However, these agents have achieved little clinical success, possibly due to their partial agonist character at postsynaptic 5-HT1A-Rs, together with full agonist properties at presynaptic 5-HT1A autoreceptors, as well as their gastrointestinal side effects. The partial 5-HT1A-R agonists buspirone, gepirone, and tandospirone are marketed as anxiolytic drugs, and buspirone is also used as an augmentation strategy in MDD. The development of new 5-HT1A-R agonists with selectivity for postsynaptic 5-HT1A-Rs may open new perspectives in the field.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Presynaptic 5-HT(1A) and 5HT(1B) auto-receptors play a major detrimental role in antidepressant treatments [45].”
Citations
Cites
Kessler, R. C., Berglund, P., Demler, O., Jin, R., Merikangas, K. R., & Walters, E. E. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.6.593 · Cited by 20,391
An Integrative Theory of Prefrontal Cortex Function
Miller, E. K., & Cohen, J. D. (2001) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.24.1.167 · Cited by 12,803 · cited 1×
“and exert a top-down control of their activity [39, 40], 5-HT1A-R activation in the PFC may modulate neuronal function distally, as observed with brainstem monoaminergic nuclei [23, 41, 42].”
Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene
Caspi, A., Sugden, K., Moffitt, T. E., Taylor, A., Craig, I. W., Harrington, H., McClay, J., Mill, J., Martin, J., Braithwaite, A., et al. (2003) · Science · doi:10.1126/science.1083968 · Cited by 8,120
Murray, C. J., & Lopez, A. D. (1997) · The Lancet · doi:10.1016/s0140-6736(96)07492-2 · Cited by 7,007
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
Lesch, K.-P., Bengel, D., Heils, A., Sabol, S. Z., Greenberg, B. D., Petri, S., Benjamin, J., Müller, C. R., Hamer, D. H., & Murphy, D. L. (1996) · Science · doi:10.1126/science.274.5292.1527 · Cited by 5,162
Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants
Santarelli, L., Saxe, M., Gross, C., Surget, A., Battaglia, F., Dulawa, S., Weisstaub, N., Lee, J., Duman, R., Arancio, O., et al. (2003) · Science · doi:10.1126/science.1083328 · Cited by 4,321 · cited 1×
“depends on 5-HT1A-R activation [89], but also the functional remodeling of corticolimbic circuits involved in MDD [90].”
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879 · cited 1×
“are required to obtain a clinical response in two-thirds of patients [5, 6].”
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766 · cited 1×
“The emergence of glutamatergic targets has raised considerable interest in neuropsychopharmacology [9, 10].”
A review of central 5-HT receptors and their function
Barnes, N. M., & Sharp, T. (1999) · Neuropharmacology · doi:10.1016/s0028-3908(99)00010-6 · Cited by 3,161
Structure and function of the brain serotonin system
Jacobs, B. L., & Azmitia, E. C. (1992) · Physiological Reviews · doi:10.1152/physrev.1992.72.1.165 · Cited by 2,576 · cited 2×
“during waking, ceasing their activity during rapid eye movement (REM) sleep [11].”
Nongenomic Transmission Across Generations of Maternal Behavior and Stress Responses in the Rat
Francis, D., Diorio, J., Liu, D., & Meaney, M. J. (1999) · Science · doi:10.1126/science.286.5442.1155 · Cited by 1,965
Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis
Leucht, S., Corves, C., Arbter, D., Engel, R. R., Li, C., & Davis, J. M. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61764-x · Cited by 1,930 · cited 1×
“respects [7, 8], although its widespread clinical use is prevented by rare side effects, such as agranulocytosis or”
Pazos, A., & Palacios, J. M. (1985) · Brain Research · doi:10.1016/0006-8993(85)90856-x · Cited by 1,855
Global burden of depressive disorders in the year 2000
Üstün, T. B., Ayuso-Mateos, J. L., Chatterji, S., Mathers, C., & Murray, C. J. L. (2004) · British Journal of Psychiatry · doi:10.1192/bjp.184.5.386 · Cited by 1,735
Cost of disorders of the brain in Europe 2010
Gustavsson, A., Svensson, M., Jacobi, F., Allgulander, C., Alonso, J., Beghi, E., Dodel, R., Ekman, M., Faravelli, C., Fratiglioni, L., et al. (2011) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2011.08.008 · Cited by 1,723
Modulation of memory fields by dopamine Dl receptors in prefrontal cortex
Williams, G. V., & Goldman-Rakic, P. S. (1995) · Nature · doi:10.1038/376572a0 · Cited by 1,593 · cited 1×
“observed with dopamine D1 receptors [179].”
Regional dissociations within the hippocampus-memory and anxiety
Bannerman, D. M., Rawlins, J. N. P., McHugh, S. B., Deacon, R. M. J., Yee, B. K., Bast, T., Zhang, W.-N., Pothuizen, H. H. J., & Feldon, J. (2004) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2004.03.004 · Cited by 1,462
Farde, L. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820070032005 · Cited by 1,419
Maternal care, hippocampal synaptogenesis and cognitive development in rats
Liu, D., Diorio, J., Day, J. C., Francis, D. D., & Meaney, M. J. (2000) · Nature Neuroscience · doi:10.1038/77702 · Cited by 1,195
Roth, B. L., Sheffler, D. J., & Kroeze, W. K. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1346 · Cited by 1,155 · cited 1×
“drugs display variable affinity for 5-HT1A-Rs [166], they increase PFC dopamine release by a postsynaptic 5-HT1AR-dependent mechanism [41, 167–170].”
Cryan, J. F., Valentino, R. J., & Lucki, I. (2005) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2005.03.008 · Cited by 1,119
Current advances and trends in the treatment of depression
Blier, P., & de Montigny, C. (1994) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(94)90315-8 · Cited by 1,113 · cited 1×
“Likewise, presynaptic 5-HT1A-R activation by SSRIs, SNRIs or 5-HT1A-R agonists reduces 5-HT neuronal activity and terminal 5-HT release [21, 59], thus limiting the activation”
Patil, S. T., Zhang, L., Martenyi, F., Lowe, S. L., Jackson, K. A., Andreev, B. V., Avedisova, A. S., Bardenstein, L. M., Gurovich, I. Y., Morozova, M. A., et al. (2007) · Nature Medicine · doi:10.1038/nm1632 · Cited by 1,040 · cited 1×
“The emergence of glutamatergic targets has raised considerable interest in neuropsychopharmacology [9, 10].”
A Meta-analysis of the Efficacy of Second-Generation Antipsychotics
Davis, J. M., Chen, N., & Glick, I. D. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.6.553 · Cited by 1,034
Medication Augmentation after the Failure of SSRIs for Depression
Trivedi, M. H., Fava, M., Wisniewski, S. R., Thase, M. E., Quitkin, F., Warden, D., Ritz, L., Nierenberg, A. A., Lebowitz, B. D., Biggs, M. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052964 · Cited by 1,002 · cited 2×
“Buspirone, used mainly as an anxiolytic, has been successfully used as an augmentation strategy in SSRI-resistant MDD [101], possibly due to its ability to stimulate catecholamine release via cortical 5-HT1A-Rs [41, 43].”
The neurobiology and control of anxious states
Millan, M. J. (2003) · Progress in Neurobiology · doi:10.1016/s0301-0082(03)00087-x · Cited by 965 · cited 1×
“5-HT1A-Rs in adulthood does not evoke anxious behavior [131].”
Adult brain neurogenesis and psychiatry: a novel theory of depression
Jacobs, B. L., van Praag, H., & Gage, F. H. (2000) · Molecular Psychiatry · doi:10.1038/sj.mp.4000712 · Cited by 964 · cited 1×
“The antidepressant effects of 5-HT1A-R stimulation may be related to the induction of hippocampal neurogenesis, a common feature of antidepressant treatments [88], which”
Reduced fear expression after lesions of the ventral hippocampus
Kjelstrup, K. G., Tuvnes, F. A., Steffenach, H.-A., Murison, R., Moser, E. I., & Moser, M.-B. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.152112399 · Cited by 912
Serotonin1A receptor acts during development to establish normal anxiety-like behaviour in the adult
Gross, C., Zhuang, X., Stark, K., Ramboz, S., Oosting, R., Kirby, L., Santarelli, L., Beck, S., & Hen, R. (2002) · Nature · doi:10.1038/416396a · Cited by 903 · cited 1×
“79], while early post-natal expression of forebrain 5-HT1ARs in 5-HT1A-R-null mice rescues the normal anxiety-like phenotype [132].”
Rush, A. J. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.11.1905 · Cited by 870 · cited 1×
“are required to obtain a clinical response in two-thirds of patients [5, 6].”
A G Protein Couples Serotonin and GABA B Receptors to the Same Channels in Hippocampus
Andrade, R., Malenka, R. C., & Nicoll, R. A. (1986) · Science · doi:10.1126/science.2430334 · Cited by 865 · cited 1×
“Postsynaptic 5-HT1A-Rs are coupled to various members of the Gi/o protein family [46, 47], thus stimulating inhibitory intracellular signaling mechanisms [48, 49].”
Electrophysiological responses of serotoninergic dorsal raphe neurons to 5‐HT1A and 5‐HT1B agonists
Sprouse, J. S., & Aghajanian, G. K. (1987) · Synapse · doi:10.1002/syn.890010103 · Cited by 845
Serotonin-dopamine interaction and its relevance to schizophrenia
(1996) · American Journal of Psychiatry · doi:10.1176/ajp.153.4.466 · Cited by 823
Serotonin receptor 1A knockout: An animal model of anxiety-related disorder
Ramboz, S., Oosting, R., Amara, D. A., Kung, H. F., Blier, P., Mendelsohn, M., Mann, J. J., Brunner, D., & Hen, R. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.24.14476 · Cited by 814 · cited 1×
“The full deletion of the 5-HT1A-R gene evokes anxious behavior [92, 93, 129].”
Lemonde, S., Turecki, G., Bakish, D., Du, L., Hrdina, P. D., Bown, C. D., Sequeira, A., Kushwaha, N., Morris, S. J., Basak, A., et al. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-25-08788.2003 · Cited by 734 · cited 1×
“The impaired suppression of 5-HT1A-autoreceptor expression may be associated with MDD [55, 56].”
Adhikari, A., Topiwala, M. A., & Gordon, J. A. (2010) · Neuron · doi:10.1016/j.neuron.2009.12.002 · Cited by 729
Leucht, S., Wahlbeck, K., Hamann, J., & Kissling, W. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13306-5 · Cited by 725
Elevated anxiety and antidepressant-like responses in serotonin 5-HT 1A receptor mutant mice
Heisler, L. K., Chu, H.-M., Brennan, T. J., Danao, J. A., Bajwa, P., Parsons, L. H., & Tecott, L. H. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.25.15049 · Cited by 709 · cited 1×
“The full deletion of the 5-HT1A-R gene evokes anxious behavior [92, 93, 129].”
López, J. F., Chalmers, D. T., Little, K. Y., & Watson, S. J. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(97)00484-8 · Cited by 699
Pompeiano, M., Palacios, J., & Mengod, G. (1992) · The Journal of Neuroscience · doi:10.1523/jneurosci.12-02-00440.1992 · Cited by 698 · cited 1×
“receptor is expressed postsynaptically to 5-HT axon terminals in the forebrain [32, 33] and the regional distribu-”
Increased anxiety of mice lacking the serotonin 1A receptor
Parks, C. L., Robinson, P. S., Sibille, E., Shenk, T., & Toth, M. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.18.10734 · Cited by 691 · cited 1×
“The full deletion of the 5-HT1A-R gene evokes anxious behavior [92, 93, 129].”
Artigas, F., Romero, L., de Montigny, C., & Blier, P. (1996) · Trends in Neurosciences · doi:10.1016/s0166-2236(96)10037-0 · Cited by 655 · cited 1×
“Likewise, presynaptic 5-HT1A-R activation by SSRIs, SNRIs or 5-HT1A-R agonists reduces 5-HT neuronal activity and terminal 5-HT release [21, 59], thus limiting the activation”
Self-citationA prefrontal cortex–brainstem neuronal projection that controls response to behavioural challenge
Warden, M. R., Selimbeyoglu, A., Mirzabekov, J. J., Lo, M., Thompson, K. R., Kim, S.-Y., Adhikari, A., Tye, K. M., Frank, L. M., & Deisseroth, K. (2012) · Nature · doi:10.1038/nature11617 · Cited by 645 · cited 1×
“lation of PFC-dorsal raphe pathways recently implicated in the selection of PFC-dependent behavioral responses [45],”
Sargent, P. A., Kjaer, K. H., Bench, C. J., Rabiner, E. A., Messa, C., Meyer, J., Gunn, R. N., Grasby, P. M., & Cowen, P. J. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.2.174 · Cited by 642 · cited 1×
“reduced postsynaptic 5-HT1A-R-mediated function, as is suggested by positron emission tomography (PET) scan studies [36, 90], yet this abnormality persists after clinical”
Araneda, R., & Andrade, R. (1991) · Neuroscience · doi:10.1016/0306-4522(91)90128-b · Cited by 625 · cited 1×
“pyramidal neurons due to the direct stimulation of 5-HT1ARs located on the recorded cells [50], in agreement with the inhibitory actions of 5-HT1A-R activation [51].”
5-HT1A receptor function in major depressive disorder
Savitz, J., Lucki, I., & Drevets, W. C. (2009) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2009.01.009 · Cited by 574 · cited 2×
“depends on 5-HT1A-R activation [89], but also the functional remodeling of corticolimbic circuits involved in MDD [90].”
Banasr, M., Hery, M., Printemps, R., & Daszuta, A. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300320 · Cited by 539
Is there a role for 5-HT1A agonists in the treatment of depression?
Blier, P., & Ward, N. M. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01643-8 · Cited by 529 · cited 1×
“ments tonically activate hippocampal 5-HT1A-Rs [82, 83].”
Artigas, F. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030084009 · Cited by 510
Self-citationCelada, P., Puig, M. V., Casanovas, J. M., Guillazo, G., & Artigas, F. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-24-09917.2001 · Cited by 497 · cited 3×
“and exert a top-down control of their activity [39, 40], 5-HT1A-R activation in the PFC may modulate neuronal function distally, as observed with brainstem monoaminergic nuclei [23, 41, 42].”
Self-citationIchikawa, J., Ishii, H., Bonaccorso, S., Fowler, W. L., O'Laughlin, I. A., & Meltzer, H. Y. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00154.x · Cited by 494 · cited 1×
“direct or indirect agonist activity at 5-HT1A-Rs [41, 196, 197], supporting the involvement of 5-HT1A-Rs in their therapeutic effects.”
Leucht, S., Komossa, K., Rummel-Kluge, C., Corves, C., Hunger, H., Schmid, F., Asenjo Lobos, C., Schwarz, S., & Davis, J. M. (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.08030368 · Cited by 490 · cited 1×
“respects [7, 8], although its widespread clinical use is prevented by rare side effects, such as agranulocytosis or”
Santana, N. (2004) · Cerebral Cortex · doi:10.1093/cercor/bhh070 · Cited by 486 · cited 1×
“In rodent PFC, *50 % of pyramidal neurons and *25 % of GABAergic interneurons express 5-HT1A-Rs [37], and this proportion is even higher (up to 80 %) in upper”
Kalinichev, M., Easterling, K. W., Plotsky, P. M., & Holtzman, S. G. (2002) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(02)00781-5 · Cited by 484
The monoamine innervation of rat cerebral cortex: Synaptic and nonsynaptic axon terminals
Beaudet, A., & Descarries, L. (1978) · Neuroscience · doi:10.1016/0306-4522(78)90115-x · Cited by 451
Albert, P. R., Zhou, Q. Y., Van Tol, H. H., Bunzow, J. R., & Civelli, O. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)39437-2 · Cited by 450 · cited 1×
“5-HT1A-Rs are encoded by an intronless gene, therefore lacking splice variants [53].”
5-HT1A autoreceptor levels determine vulnerability to stress and response to antidepressants
Richardson-Jones, J. W., Craige, C. P., Guiard, B. P., Stephen, A., Metzger, K. L., Kung, H. F., Gardier, A. M., Dranovsky, A., David, D. J., Beck, S. G., et al. (2010) · Neuron · doi:10.1016/j.neuron.2009.12.003 · Cited by 450 · cited 1×
“5-HT1A-R—without altering postsynaptic 5-HT1A-R—is sufficient to evoke antidepressant-like effects in mice [24, 78, 79],”
The prefrontal cortex and the integration of sensory, limbic and autonomic information
Groenewegen, H. J., & Uylings, H. B. M. (2000) · Progress in Brain Research · doi:10.1016/s0079-6123(00)26003-2 · Cited by 442 · cited 1×
“and exert a top-down control of their activity [39, 40], 5-HT1A-R activation in the PFC may modulate neuronal function distally, as observed with brainstem monoaminergic nuclei [23, 41, 42].”
Stockmeier, C. A., Shapiro, L. A., Dilley, G. E., Kolli, T. N., Friedman, L., & Rajkowska, G. (1998) · The Journal of Neuroscience · doi:10.1523/jneurosci.18-18-07394.1998 · Cited by 429
Blier, P., & De Montigny, C. (1987) · Synapse · doi:10.1002/syn.890010511 · Cited by 426
Neuropeptide systems as novel therapeutic targets for depression and anxiety disorders
Holmes, A., Heilig, M., Rupniak, N. M. J., Steckler, T., & Griebel, G. (2003) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2003.09.011 · Cited by 403
Sarnyai, Z., Sibille, E. L., Pavlides, C., Fenster, R. J., McEwen, B. S., & Tóth, M. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.26.14731 · Cited by 396
Amargos-Bosch, M. (2004) · Cerebral Cortex · doi:10.1093/cercor/bhg128 · Cited by 370 · cited 1×
“Interestingly, 5-HT1A-Rs are abundantly coexpressed with excitatory 5-HT2A-Rs in rodent PFC [44].”
Champoux, M., Bennett, A., Shannon, C., Higley, J. D., Lesch, K. P., & Suomi, S. J. (2002) · Molecular Psychiatry · doi:10.1038/sj.mp.4001157 · Cited by 366
Malizia, A. L., Cunningham, V. J., Bell, C. J., Liddle, P. F., Jones, T., & Nutt, D. J. (1998) · Archives of General Psychiatry · doi:10.1001/archpsyc.55.8.715 · Cited by 361
Serotonin4 (5-HT4) Receptor Agonists Are Putative Antidepressants with a Rapid Onset of Action
Lucas, G., Rymar, V. V., Du, J., Mnie-Filali, O., Bisgaard, C., Manta, S., Lambas-Senas, L., Wiborg, O., Haddjeri, N., Piñeyro, G., et al. (2007) · Neuron · doi:10.1016/j.neuron.2007.07.041 · Cited by 359 · cited 1×
“, 5-HT4-R) [97] (see a recent review, Artigas [98], for the role of the various 5-HT receptors in the”
Reduced Serotonin Type 1AReceptor Binding in Panic Disorder: Figure 1.
Neumeister, A., Bain, E., Nugent, A. C., Carson, R. E., Bonne, O., Luckenbaugh, D. A., Eckelman, W., Herscovitch, P., Charney, D. S., & Drevets, W. C. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.4921-03.2004 · Cited by 355
The role of 5-HT1A receptors in learning and memory
Ögren, S. O., Eriksson, T. M., Elvander-Tottie, E., D’Addario, C., Ekström, J. C., Svenningsson, P., Meister, B., Kehr, J., & Stiedl, O. (2008) · Behavioural Brain Research · doi:10.1016/j.bbr.2008.02.023 · Cited by 340
(1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.10.1444 · Cited by 339
Sprouse, J. S., & Aghajanian, G. K. (1988) · Neuropharmacology · doi:10.1016/0028-3908(88)90079-2 · Cited by 333 · cited 1×
“) are full agonists at raphe 5-HT1ARs and partial agonists at postsynaptic hippocampal 5-HT1ARs [62].”
Long-Term Antidepressant Treatments Result in a Tonic Activation of Forebrain 5-HT1AReceptors
Haddjeri, N., Blier, P., & de Montigny, C. (1998) · The Journal of Neuroscience · doi:10.1523/jneurosci.18-23-10150.1998 · Cited by 332 · cited 1×
“ments tonically activate hippocampal 5-HT1A-Rs [82, 83].”
Epigenetic sources of behavioral differences in mice
Francis, D. D., Szegda, K., Campbell, G., Martin, W. D., & Insel, T. R. (2003) · Nature Neuroscience · doi:10.1038/nn1038 · Cited by 332
Singewald, N., Salchner, P., & Sharp, T. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01574-3 · Cited by 322 · cited 1×
“PFC dysfunction is suggested in anxiety disorders [141–144], and altered neuronal activity is associated with anxiety in rodents [145, 146].”
Sharp, T., Bramwell, S. R., & Grahame‐Smith, D. G. (1989) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1989.tb11815.x · Cited by 321
Serotonin receptors involved in antidepressant effects
Artigas, F. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.09.006 · Cited by 311 · cited 3×
“, 5-HT4-R) [97] (see a recent review, Artigas [98], for the role of the various 5-HT receptors in the”
Self-citationReduced Serotonin-1A Receptor Binding in Social Anxiety Disorder
Lanzenberger, R. R., Mitterhauser, M., Spindelegger, C., Wadsak, W., Klein, N., Mien, L.-K., Holik, A., Attarbaschi, T., Mossaheb, N., Sacher, J., et al. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.05.022 · Cited by 300
Pérez, V., Gilaberte, I., Faries, D., Alvarez, E., & Artigas, F. (1997) · The Lancet · doi:10.1016/s0140-6736(96)08007-5 · Cited by 300
Self-citationImproving the Treatment of Schizophrenia: Focus on Serotonin (5-HT)1A Receptors
Millan, M. J. (2000) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38982-7 · Cited by 287
Burnet, P. (1996) · Neuropsychopharmacology · doi:10.1016/s0893-133x(96)00053-x · Cited by 286
Díaz-Mataix, L., Scorza, M. C., Bortolozzi, A., Toth, M., Celada, P., & Artigas, F. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.2999-05.2005 · Cited by 285 · cited 7×
“direct or indirect agonist activity at 5-HT1A-Rs [41, 196, 197], supporting the involvement of 5-HT1A-Rs in their therapeutic effects.”
InfluentialSelf-citationMørk, A., Pehrson, A., Brennum, L. T., Nielsen, S. M., Zhong, H., Lassen, A. B., Miller, S., Westrich, L., Boyle, N. J., Sánchez, C., et al. (2012) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.111.189068 · Cited by 271
The role of serotonin receptor subtypes in treating depression: a review of animal studies
Carr, G. V., & Lucki, I. (2011) · Psychopharmacology · doi:10.1007/s00213-010-2097-z · Cited by 260
Winstanley, C. A., Dalley, J. W., Theobald, D. E. H., & Robbins, T. W. (2003) · Psychopharmacology · doi:10.1007/s00213-003-1546-3 · Cited by 256 · cited 1×
“process [186], 5-HT1A-R activation in the hippocampus may impair some forms of memory [187].”
Origin and functional role of the extracellular serotonin in the midbrain raphe nuclei
Adell, A., Celada, P., Abellán, M. T., & Artigas, F. (2002) · Brain Research Reviews · doi:10.1016/s0165-0173(02)00182-0 · Cited by 254 · cited 1×
“peptidergic and local GABAergic inputs [13].”
Self-citationBhagwagar, Z., Rabiner, E. A., Sargent, P. A., Grasby, P. M., & Cowen, P. J. (2004) · Molecular Psychiatry · doi:10.1038/sj.mp.4001401 · Cited by 254
The recombinant 5‐HT1A receptor: G protein coupling and signalling pathways
Raymond, J. R., Mukhin, Y. V., Gettys, T. W., & Garnovskaya, M. N. (1999) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0702723 · Cited by 239 · cited 1×
“Postsynaptic 5-HT1A-Rs are coupled to various members of the Gi/o protein family [46, 47], thus stimulating inhibitory intracellular signaling mechanisms [48, 49].”
Bel, N., & Artigas, F. (1993) · Synapse · doi:10.1002/syn.890150310 · Cited by 237
Self-citationPuig, M. V. (2004) · Cerebral Cortex · doi:10.1093/cercor/bhh104 · Cited by 231 · cited 1×
“pyramidal neurons due to the direct stimulation of 5-HT1ARs located on the recorded cells [50], in agreement with the inhibitory actions of 5-HT1A-R activation [51].”
5-HT1A receptor-regulated signal transduction pathways in brain
Polter, A. M., & Li, X. (2010) · Cellular Signalling · doi:10.1016/j.cellsig.2010.03.019 · Cited by 225 · cited 1×
“Postsynaptic 5-HT1A-Rs are coupled to various members of the Gi/o protein family [46, 47], thus stimulating inhibitory intracellular signaling mechanisms [48, 49].”
Adell, A., & Artigas, F. (1991) · Naunyn-Schmiedeberg's Archives of Pharmacology · doi:10.1007/bf00251121 · Cited by 222
Self-citationThe 5-HT1A receptor in schizophrenia: a promising target for novel atypical neuroleptics?
Bantick, R. A., Deakin, J. F. W., & Grasby, P. M. (2001) · Journal of Psychopharmacology · doi:10.1177/026988110101500108 · Cited by 214
Hajós, M., Hajós‐Korcsok, É., & Sharp, T. (1999) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0702510 · Cited by 210
Mayorga, A. J., Dalvi, A., Page, M. E., Zimov-Levinson, S., Hen, R., & Lucki, I. (2001) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29479-9 · Cited by 209
Sumiyoshi, T., Matsui, M., Nohara, S., Yamashita, I., Kurachi, M., Sumiyoshi, C., Jayathilake, K., & Meltzer, H. Y. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.10.1722 · Cited by 207
Auerbach, J., Geller, V, Lezer, S., Shinwell, E., Belmaker, R. H., Levine, J., & Ebstein, R. P. (1999) · Molecular Psychiatry · doi:10.1038/sj.mp.4000531 · Cited by 205
Clozapine increases dopamine release in prefrontal cortex by 5-HT1A receptor activation
Rollema, H., Lu, Y., Schmidt, A. W., & Zorn, S. H. (1997) · European Journal of Pharmacology · doi:10.1016/s0014-2999(97)81951-6 · Cited by 203 · cited 1×
“mediated by 5-HT1A-R activation [167] and does not depend on the presence of 5-HT2A-R [41, 170].”
Targeted gene mutation approaches to the study of anxiety-like behavior in mice
Holmes, A. (2001) · Neuroscience & Biobehavioral Reviews · doi:10.1016/s0149-7634(01)00012-4 · Cited by 197
Shah, A. A., & Treit, D. (2003) · Brain Research · doi:10.1016/s0006-8993(03)02299-6 · Cited by 196 · cited 1×
“PFC dysfunction is suggested in anxiety disorders [141–144], and altered neuronal activity is associated with anxiety in rodents [145, 146].”
Rollema, H., Lu, Y., Schmidt, A. W., Sprouse, J. S., & Zorn, S. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(00)00850-7 · Cited by 195
Richardson-Jones, J. W., Craige, C. P., Nguyen, T. H., Kung, H. F., Gardier, A. M., Dranovsky, A., David, D. J., Guiard, B. P., Beck, S. G., Hen, R., et al. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.5836-10.2011 · Cited by 192 · cited 2×
“Also, genetic studies indicate that postsynaptic 5-HT1A-Rs are sufficient for antidepressant-like effects in rodents [84].”
Dilger, S., Straube, T., Mentzel, H.-J., Fitzek, C., Reichenbach, J. R., Hecht, H., Krieschel, S., Gutberlet, I., & Miltner, W. H. R. (2003) · Neuroscience Letters · doi:10.1016/s0304-3940(03)00647-5 · Cited by 190
Sibille, E., Pavlides, C., Benke, D., & Toth, M. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-08-02758.2000 · Cited by 183 · cited 1×
“reported in 5-HT1A-R knockout mice [138, 147, 148].”
Serotonin 5-HT1A receptor binding in people with panic disorder: positron emission tomography study
Nash, J. R., Sargent, P. A., Rabiner, E. A., Hood, S. D., Argyropoulos, S. V., Potokar, J. P., Grasby, P. M., & Nutt, D. J. (2008) · British Journal of Psychiatry · doi:10.1192/bjp.bp.107.041186 · Cited by 177
How does pindolol improve antidepressant action?
Artigas, F., Celada, P., Laruelle, M., & Adell, A. (2001) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(00)01682-5 · Cited by 174
Self-citationBurnet, P. (1997) · Neurochemistry International · doi:10.1016/s0197-0186(96)00124-6 · Cited by 174
Newman‐Tancredi, A., & Kleven, M. S. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2247-y · Cited by 174 · cited 1×
“that the balance between 5-HT1A-R and D2-R properties is critical for the activity of these drugs in preclinical models [198].”
Does stimulation of 5-HT1A receptors improve cognition in schizophrenia?
Meltzer, H. Y., & Sumiyoshi, T. (2008) · Behavioural Brain Research · doi:10.1016/j.bbr.2008.05.016 · Cited by 172 · cited 1×
“deficits, as observed in some clinical studies [172].”
SPECT [I-123]iomazenil measurement of the benzodiazepine receptor in panic disorder
Bremner, J. D., Innis, R. B., White, T., Fujita, M., Silbersweig, D., Goddard, A. W., Staib, L., Stern, E., Cappiello, A., Woods, S., et al. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00188-2 · Cited by 170
Parsey, R. V., Ogden, R. T., Miller, J. M., Tin, A., Hesselgrave, N., Goldstein, E., Mikhno, A., Milak, M., Zanderigo, F., Sullivan, G. M., et al. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.03.023 · Cited by 170 · cited 1×
“higher binding potential of presynaptic 5-HT1A-R than controls [58].”
Genetic animal models of anxiety
Finn, D. A., Rutledge-Gorman, M. T., & Crabbe, J. C. (2003) · Neurogenetics · doi:10.1007/s10048-003-0143-2 · Cited by 166
Serotonin1A receptors are increased in postmortem prefrontal cortex in schizophrenia
Sumiyoshi, T., Stockmeier, C. A., Overholser, J. C., Dilley, G. E., & Meltzer, H. Y. (1996) · Brain Research · doi:10.1016/0006-8993(95)01361-x · Cited by 163
Functional MRI changes during panic anticipation and imagery exposure
Bystritsky, A., Pontillo, D., Powers, M., Sabb, F. W., Craske, M. G., & Bookheimer, S. Y. (2001) · Neuroreport · doi:10.1097/00001756-200112210-00020 · Cited by 162
Ultrastructural localization of 5-hydroxytryptamine1A receptors in the rat brain
Kia, H. K., Brisorgueil, M.-J., Hamon, M., Calas, A., & Verg�, D. (1996) · Journal of Neuroscience Research · doi:10.1002/(sici)1097-4547(19961215)46:6<697::aid-jnr7>3.0.co;2-a · Cited by 160 · cited 1×
“receptor is expressed postsynaptically to 5-HT axon terminals in the forebrain [32, 33] and the regional distribu-”
Llado-Pelfort, L., Santana, N., Ghisi, V., Artigas, F., & Celada, P. (2012) · Cerebral Cortex · doi:10.1093/cercor/bhr220 · Cited by 156 · cited 1×
“5-HT1A-Rs in fast-spiking GABA interneurons by low doses of 5-HTA-R agonists, leading to pyramidal neuron disinhibition [69] (Fig.”
Self-citationQuantified distribution of the serotonin innervation in adult rat hippocampus
Oleskevich, S., & Descarries, L. (1990) · Neuroscience · doi:10.1016/0306-4522(90)90301-j · Cited by 153 · cited 1×
“, 1–4 9 10(6) serotonergic varicosities/mm(3) [15] in rat hip-”
Romero, L., & Artigas, F. (1997) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1997.68062593.x · Cited by 152
Self-citationSumiyoshi, T., Park, S., Jayathilake, K., Roy, A., Ertuğrul, A., & Meltzer, H. Y. (2007) · Schizophrenia Research · doi:10.1016/j.schres.2007.06.008 · Cited by 147
Pollack, M. H., Simon, N. M., Zalta, A. K., Worthington, J. J., Hoge, E. A., Mick, E. O., Kinrys, G., & Oppenheimer, J. E. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.07.005 · Cited by 146
Bortolozzi, A. A., Castañé, A., Semakova, J., Santana, N., Alvarado, G., Cortés, R., Ferrés‐Coy, A., Fernández, G., Carmona, M. C., Tóth, M., et al. (2011) · Molecular Psychiatry · doi:10.1038/mp.2011.92 · Cited by 145 · cited 1×
“5-HT1A-R—without altering postsynaptic 5-HT1A-R—is sufficient to evoke antidepressant-like effects in mice [24, 78, 79],”
Self-citationReduced anxiety-related behaviour in transgenic mice overexpressing serotonin1A receptors
Kusserow, H., Davies, B., Hörtnagl, H., Voigt, I., Stroh, T., Bert, B., Deng, D. R., Fink, H., Veh, R. W., & Theuring, F. (2004) · Molecular Brain Research · doi:10.1016/j.molbrainres.2004.06.028 · Cited by 145 · cited 1×
“5-HT1A-Rs reduces anxiety in mice [133].”
Azapirones for generalized anxiety disorder
Chessick, C. A., Allen, M. H., Thase, M. E., Batista Miralha da Cunha, A. A., Kapczinski, F., Silva de Lima, M., & dos Santos Souza, J. J. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006115 · Cited by 144 · cited 1×
“patients not treated before with benzodiazepines [105].”
Anxiolytic effects of cytotoxic hippocampal lesions in rats.
Deacon, R. M. J., Bannerman, D. M., & Rawlins, J. N. P. (2002) · Behavioral Neuroscience · doi:10.1037//0735-7044.116.3.494 · Cited by 141
Pertussis toxin blocks 5-HT1A and GABAB receptor-mediated inhibition of serotonergic neurons
Innis, R. B., & Aghajanian, G. K. (1987) · European Journal of Pharmacology · doi:10.1016/0014-2999(87)90533-4 · Cited by 141 · cited 1×
“to these local and distal inputs, a key mechanism of control is auto-inhibition through 5-HT1A autoreceptors, coupled to Gi/o proteins [17].”
Riad, M. (2004) · Journal of Neuroscience · doi:10.1523/jneurosci.0950-04.2004 · Cited by 141
Meneses, A., & Perez-Garcia, G. (2007) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2007.02.001 · Cited by 141 · cited 3×
“Hence, low doses of 5-HT1A-R agonists display pro-cognitive effects (for review, see Meneses and Perez-Garcia [175]).”
Adell, A., Carceller, A., & Artigas, F. (1993) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1993.tb13390.x · Cited by 136
Self-citationTauscher, J., Bagby, R. M., Javanmard, M., Christensen, B. K., Kasper, S., & Kapur, S. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.8.1326 · Cited by 134 · cited 1×
“forebrain 5-HT1A-Rs in the development of anxious phenotypes [125, 126].”
Tauscher, J., Kapur, S., Verhoeff, N. P. L. G., Hussey, D. F., Daskalakis, Z. J., Tauscher-Wisniewski, S., Wilson, A. A., Houle, S., Kasper, S., & Zipursky, R. B. (2002) · Archives of General Psychiatry · doi:10.1001/archpsyc.59.6.514 · Cited by 132 · cited 1×
“Postmortem [149–152] and neuroimage studies [153, 154] reveal alterations in 5-HT1A-R density in the cortex and amygdala of schizophrenic”
Martinez, D., Hwang, D., Mawlawi, O., Slifstein, M., Kent, J., Simpson, N., Parsey, R. V., Hashimoto, T., Huang, Y., Shinn, A., et al. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(00)00187-1 · Cited by 130
Newman‐Tancredi, A., Martel, J., Assié, M., Buritova, J., Lauressergues, E., Cosi, C., Heusler, P., Bruins Slot, L., Colpaert, F., Vacher, B., et al. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2008.00001.x · Cited by 128
Invernizzi, R. W., Cervo, L., & SAMANIN, R. (1988) · Neuropharmacology · doi:10.1016/0028-3908(88)90134-7 · Cited by 128
Huang, C.-C., Liang, Y.-C., & Hsu, K.-S. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-22-09728.1999 · Cited by 127
Inhibitory Effect of Hippocampal 5-HT1A Receptors on Human Explicit Memory
Yasuno, F., Suhara, T., Nakayama, T., Ichimiya, T., Okubo, Y., Takano, A., Ando, T., Inoue, M., Maeda, J., & Suzuki, K. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.2.334 · Cited by 123 · cited 1×
“process [186], 5-HT1A-R activation in the hippocampus may impair some forms of memory [187].”
Ashby, C. R., Edwards, E., & Wang, R. Y. (1994) · Synapse · doi:10.1002/syn.890170306 · Cited by 116 · cited 1×
“5-HT1A-R agonists inhibits the activity of putative pyramidal neurons in PFC [52] (however, see Sect.”
Hervás, I. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(00)00175-5 · Cited by 115
Simpson, M. D. C., Lubman, D. I., Slater, P., & Deakin, J. F. W. (1996) · Biological Psychiatry · doi:10.1016/0006-3223(95)00026-7 · Cited by 115
Clozapine is a partial agonist at cloned, human serotonin 5-HT1A receptors
Newman‐Tancredi, A., Chaput, C., Verrièle, L., & Millan, M. J. (1996) · Neuropharmacology · doi:10.1016/0028-3908(95)00170-0 · Cited by 114 · cited 1×
“Although it shows moderate (160–700 nM) in vitro affinity [192], clozapine occupies 5-HT1A-Rs in the monkey brain at clinical doses [193] and it displays agonist properties at 5-HT1A-Rs in various experimental models [194, 195].”
Kishi, T., Yoshimura, R., Fukuo, Y., Okochi, T., Matsunaga, S., Umene‐Nakano, W., Nakamura, J., Serretti, A., Correll, C. U., Kane, J. M., et al. (2012) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-012-0337-4 · Cited by 112 · cited 1×
“The impaired suppression of 5-HT1A-autoreceptor expression may be associated with MDD [55, 56].”
Evidence for HTR1A and LHPP as interacting genetic risk factors in major depression
Neff, C. D., Abkevich, V., Packer, J. C. L., Chen, Y., Potter, J., Riley, R., Davenport, C., Warren, J., Jammulapati, S., Bhathena, A., et al. (2008) · Molecular Psychiatry · doi:10.1038/mp.2008.8 · Cited by 110
Therapeutic Role of 5-HT1A Receptors in The Treatment of Schizophrenia and Parkinson's Disease
Ohno, Y. (2011) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2010.00211.x · Cited by 108
Decreased 5-HT1A receptor binding in amygdala of schizophrenia
Yasuno, F., Suhara, T., Ichimiya, T., Takano, A., Ando, T., & Okubo, Y. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2003.11.016 · Cited by 107
In vivo actions of aripiprazole on serotonergic and dopaminergic systems in rodent brain
Bortolozzi, A. A., Díaz-Mataix, L., Tóth, M., Celada, P., & Artigas, F. (2007) · Psychopharmacology · doi:10.1007/s00213-007-0698-y · Cited by 106 · cited 1×
“direct or indirect agonist activity at 5-HT1A-Rs [41, 196, 197], supporting the involvement of 5-HT1A-Rs in their therapeutic effects.”
Self-citationMartin, P., Beninger, R. J., Hamon, M., & Puech, A. J. (1990) · Behavioural Brain Research · doi:10.1016/0166-4328(90)90011-3 · Cited by 105
Casanovas, J. M., Lésourd, M., & Artigas, F. (1997) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0701420 · Cited by 104
Self-citationLladó‐Pelfort, L., Assié, M., Newman‐Tancredi, A., Artigas, F., & Celada, P. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00738.x · Cited by 103 · cited 1×
“5-HT1A-R agonists also increase PFC dopamine release by activating local 5-HT1A-Rs and increasing the activity of mesocortical dopamine neurons [41, 64] (Fig.”
Self-citationVazquez-Borsetti, P., Cortes, R., & Artigas, F. (2009) · Cerebral Cortex · doi:10.1093/cercor/bhn204 · Cited by 103
Self-citationModifying 5-HT1A receptor gene expression as a new target for antidepressant therapy
Albert (2010) · Frontiers in Neuroscience · doi:10.3389/fnins.2010.00035 · Cited by 103 · cited 1×
“scriptional regulation has been reported for pre- and postsynaptic 5-HT1A-Rs since a C(-1019)G 5-HT1A-R promoter polymorphism prevents the repression of the 5-HT1A-R gene in serotonergic neurons [54].”
Depoortère, R., Auclair, A. L., Bardin, L., Colpaert, F. C., Vacher, B., & Newman‐Tancredi, A. (2010) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2010.04.005 · Cited by 101
An Open Trial of Buspirone Added to Neuroleptics in Schizophrenic Patients
GOFF, D. C., Midha, K. K., Brotman, A. W., Mccormick, S., WAITES, M., & AMICO, E. T. (1991) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199106000-00008 · Cited by 98
Page, M. E., Cryan, J. F., Sullivan, A., Dalvi, A., Saucy, B., Manning, D. R., & Lucki, I. (2002) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.034280 · Cited by 95
Horiguchi, M., & Meltzer, H. Y. (2012) · Psychopharmacology · doi:10.1007/s00213-011-2561-4 · Cited by 91
Kasper, S., Tauscher, J., Willeit, M., Stamenkovic, M., Neumeister, A., Küfferle, B., Barnas, C., Stastny, J., Praschak-rieder, N., Pezawas, L., et al. (2002) · The World Journal of Biological Psychiatry · doi:10.3109/15622970209150614 · Cited by 91 · cited 1×
“Postmortem [149–152] and neuroimage studies [153, 154] reveal alterations in 5-HT1A-R density in the cortex and amygdala of schizophrenic”
Bortolozzi, A., Masana, M., Díaz-Mataix, L., Cortés, R., Scorza, M. C., Gingrich, J. A., Toth, M., & Artigas, F. (2010) · The International Journal of Neuropsychopharmacology · doi:10.1017/s146114571000009x · Cited by 88 · cited 1×
“mediated by 5-HT1A-R activation [167] and does not depend on the presence of 5-HT2A-R [41, 170].”
Self-citation5-HT1A Receptor, an Old Target for New Therapeutic Agents
Lacivita, E., Leopoldo, M., Berardi, F., & Perrone, R. (2008) · Current Topics in Medicinal Chemistry · doi:10.2174/156802608785161385 · Cited by 87
Newman-Tancredi, A. (2011) · Neuropsychiatry · doi:10.2217/npy.11.12 · Cited by 86
Ferrés‐Coy, A., Santana, N., Castañé, A., Cortés, R., Carmona, M. C., Tóth, M., Montefeltro, A., Artigas, F., & Bortolozzi, A. A. (2012) · Psychopharmacology · doi:10.1007/s00213-012-2795-9 · Cited by 85 · cited 2×
“5-HT1A-R—without altering postsynaptic 5-HT1A-R—is sufficient to evoke antidepressant-like effects in mice [24, 78, 79],”
Self-citationBatten, S. V., Aslan, M., Maciejewski, P. K., & Mazure, C. M. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0216 · Cited by 84
State-Dependent Alterations in Hippocampal Oscillations in Serotonin 1A Receptor-Deficient Mice
Gordon, J. A., Lacefield, C. O., Kentros, C. G., & Hen, R. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.1211-05.2005 · Cited by 81
Lo Iacono, L., & Gross, C. (2008) · Journal of Neuroscience · doi:10.1523/jneurosci.5219-07.2008 · Cited by 81
Czesak, M., Le François, B., Millar, A. M., Deria, M., Daigle, M., Visvader, J. E., Anisman, H., & Albert, P. R. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.293027 · Cited by 80
de Almeida, J., & Mengod, G. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05649.x · Cited by 76 · cited 1×
“cortical layers of primate and human PFC [38].”
Brain Serotonin1A Receptor Binding in Major Depression Is Related to Psychic and Somatic Anxiety
Sullivan, G. M., Oquendo, M. A., Simpson, N. R., Heertum, R. L. V., Mann, J. J., & Parsey, R. V. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.05.006 · Cited by 74 · cited 1×
“forebrain 5-HT1A-Rs in the development of anxious phenotypes [125, 126].”
Casanovas, J. M., & Artigas, F. (1996) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1996.67051945.x · Cited by 72
Self-citationWarburton, P., Baird, G., Chen, W., Morris, K., Jacobs, B. W., Hodgson, S., & Docherty, Z. (2000) · American Journal of Medical Genetics · doi:10.1002/(sici)1096-8628(20000403)96:2<228::aid-ajmg20>3.0.co;2-g · Cited by 72
High-Efficacy 5-HT1A Agonists for Antidepressant Treatment: A Renewed Opportunity
Maurel, J.-L., Autin, J.-M., Funes, P., Newman‐Tancredi, A., Colpaert, F. C., & Vacher, B. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm070714l · Cited by 70 · cited 1×
“Buspirone and PRX-00023 (selective yet partial 5-HT1A-R agonist [202]) are being explored in the treatment of epilepsy.”
Kojima, T., Matsumoto, M., Togashi, H., Tachibana, K., Kemmotsu, O., & Yoshioka, M. (2002) · Brain Research · doi:10.1016/s0006-8993(02)03756-3 · Cited by 69
Whale, R., Terao, T., Cowen, P., Freemantle, N., & Geddes, J. (2010) · Journal of Psychopharmacology · doi:10.1177/0269881108097714 · Cited by 68
Gobert, A., Lejeune, F., Rivet, J. M., Audinot, V, Newman-Tancredi, A., & Millan, M. J. (1995) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)09547-3 · Cited by 68
Sakai, N., & Tanaka, C. (1993) · Brain Research · doi:10.1016/0006-8993(93)90921-9 · Cited by 66
Portella, M. J., de Diego-Adeliño, J., Ballesteros, J., Puigdemont, D., Oller, S., Santos, B., Álvarez, E., Artigas, F., & Pérez, V. (2011) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.09m05827blu · Cited by 63
Self-citationThe prefrontal cortex: a target for antipsychotic drugs
Artigas, F. (2009) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2009.01455.x · Cited by 61
Self-citationThe serotonin 1A receptor gene as a genetic and prenatal maternal environmental factor in anxiety
Gleason, G., Liu, B., Bruening, S., Zupan, B., Auerbach, A., Mark, W., Oh, J.-E., Gal-Toth, J., Lee, F., & Toth, M. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0914805107 · Cited by 61
Mössner, R., Schuhmacher, A., Kühn, K.-U., Cvetanovska, G., Rujescu, D., Zill, P., Quednow, B. B., Rietschel, M., Wölwer, W., Gaebel, W., et al. (2009) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e328311a917 · Cited by 60 · cited 1×
“Likewise, the functional C-1019G polymorphism of the 5-HT1A-R gene is involved in the response to atypical antipsychotic drugs [156], and the”
Mori, K., Togashi, H., Kojima, T., Matsumoto, M., Ohashi, S., Ueno, K.-I., & Yoshioka, M. (2001) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(01)00546-9 · Cited by 59
Depoortère, R., Auclair, A. L., Bardin, L., Slot, L. B., Kleven, M. S., Colpaert, F., Vacher, B., & Newman‐Tancredi, A. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707160 · Cited by 55
Assié, M., Cosi, C., & Koek, W. (1997) · European Journal of Pharmacology · doi:10.1016/s0014-2999(97)01207-7 · Cited by 55 · cited 1×
“Although it shows moderate (160–700 nM) in vitro affinity [192], clozapine occupies 5-HT1A-Rs in the monkey brain at clinical doses [193] and it displays agonist properties at 5-HT1A-Rs in various experimental models [194, 195].”
Lladó-Pelfort, L., Assié, M., Newman‐Tancredi, A., Artigas, F., & Celada, P. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2569-9 · Cited by 52
Self-citationBorsini, F., Ceci, A., Bietti, G., & Donetti, A. (1995) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/bf00168558 · Cited by 52
Díaz-Mataix, L., Artigas, F., & Celada, P. (2005) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2005.10.003 · Cited by 49
Self-citationLexicon of Psychiatry, Neurology, and the Neurosciences
Ayd, F. J. (1995) · Medical Entomology and Zoology · Cited by 47
Occupancy of 5-HT1A receptors by clozapine in the primate brain: a PET study
Chou, Y.-H., Halldin, C., & Farde, L. (2003) · Psychopharmacology · doi:10.1007/s00213-002-1256-2 · Cited by 46 · cited 1×
“Although it shows moderate (160–700 nM) in vitro affinity [192], clozapine occupies 5-HT1A-Rs in the monkey brain at clinical doses [193] and it displays agonist properties at 5-HT1A-Rs in various experimental models [194, 195].”
Scorza, M., Lladó‐Pelfort, L., Oller, S., Cortés, R., Puigdemont, D., Portella, M., Pérez‐Egea, R., Alvarez, E., Celada, P., Pérez, V, et al. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01770.x · Cited by 46 · cited 1×
“patients [96], suggesting the involvement of other 5-HT receptors (e.”
Self-citationTachibana, K., Matsumoto, M., Togashi, H., Kojima, T., Morimoto, Y., Kemmotsu, O., & Yoshioka, M. (2004) · Neuroscience Letters · doi:10.1016/j.neulet.2003.11.016 · Cited by 45
Bailey, S., & Tóth, M. (2004) · Journal of Neuroscience · doi:10.1523/jneurosci.0563-04.2004 · Cited by 44 · cited 1×
“reported in 5-HT1A-R knockout mice [138, 147, 148].”
Piškulić, D., Olver, J. S., Maruff, P. T., & Norman, T. R. (2009) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.1046 · Cited by 40
Smythies, J. (2005) · International review of neurobiology · doi:10.1016/s0074-7742(05)64005-6 · Cited by 39
Stahl, S. M., Kaiser, L., Roeschen, J., Hesselink, J. M. K., & Orazem, J. P. (1998) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145798001059 · Cited by 39
Choi, Y. K., Snigdha, S., Shahid, M., Neill, J. C., & Tarazi, F. I. (2009) · Journal of Molecular Neuroscience · doi:10.1007/s12031-009-9204-9 · Cited by 39 · cited 1×
“phencyclidine-induced impairment of cognitive functions in rats is associated with cortical 5-HT1A-R upregulation [157].”
Casanovas, J. M., Berton, O., Celada, P., & Artigas, F. (2000) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s002100000291 · Cited by 38
Self-citationHajós‐Korcsok, É., & Sharp, T. (1996) · European Journal of Pharmacology · doi:10.1016/s0014-2999(96)00560-2 · Cited by 38 · cited 2×
“involved in the antidepressant actions of 5-HT1A-R agonists [41, 43].”
Treatment of cerebellar ataxia with 5‐HT1A agonist
Takei, A., Hamada, T., Yabe, I., & Sasaki, H. (2005) · The Cerebellum · doi:10.1080/14734220500222318 · Cited by 38
Sanberg, C. D., Jones, F. L., Do, V. H., Dieguez, D., & Derrick, B. E. (2006) · Learning & Memory · doi:10.1101/lm.126306 · Cited by 36
Bruening, S., Oh, E., Hetzenauer, A., Escobar‐Alvarez, S., Westphalen, R. I., Hemmings, H. C., Singewald, N., Shippenberg, T., & Toth, M. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04129.x · Cited by 35 · cited 1×
“reported in 5-HT1A-R knockout mice [138, 147, 148].”
Serotonin 5-HT1A Receptor Agonists as Antidepressants
Heiser, J. F., & Wilcox, C. S. (1998) · CNS Drugs · doi:10.2165/00023210-199810050-00004 · Cited by 32
Heusler, P., Newman‐Tancredi, A., Loock, T., & Cussac, D. (2007) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2007.11.046 · Cited by 31 · cited 1×
“Although it shows moderate (160–700 nM) in vitro affinity [192], clozapine occupies 5-HT1A-Rs in the monkey brain at clinical doses [193] and it displays agonist properties at 5-HT1A-Rs in various experimental models [194, 195].”
Lesch, K., Aulakh, C. S., Wolozin, B. L., & Murphy, D. L. (1992) · Pharmacology & Toxicology · doi:10.1111/j.1600-0773.1992.tb01629.x · Cited by 27
Multiple receptors for serotonin in the rat brain.
Hamon, M., Dl, N., Herbet, A., & Glowinski, J. (1980) · PubMed · Cited by 27
Astier, B., Lambás‐Señas, L., Soulière, F., Schmitt, P., Urbain, N., Rentero, N., Bert, L., Denoroy, L., Renaud, B., Lesourd, M., et al. (2003) · European Journal of Pharmacology · doi:10.1016/s0014-2999(02)02814-5 · Cited by 25 · cited 1×
“and exert a top-down control of their activity [39, 40], 5-HT1A-R activation in the PFC may modulate neuronal function distally, as observed with brainstem monoaminergic nuclei [23, 41, 42].”
Ansseau, M., Pitchot, W., Moreno, A. G., Wauthy, J., & Papart, P. (1993) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.470080407 · Cited by 24 · cited 1×
“pressant efficacy in pilot studies [102, 103].”
Research works printed but not linked: 1
- Greenberg BD, Li Q, Lucas FR, et al. Association between the serotonin transporter promoter polymorphism and personality traits in a primarily female population sample. Am J Med Genet. 2000;96:202–16. · DOI · Paper page
Cited by
Cannabidiol as a Potential Treatment for Anxiety Disorders
Blessing, E. M., Steenkamp, M. M., Manzanares, J., & Marmar, C. R. (2015) · Neurotherapeutics · doi:10.1007/s13311-015-0387-1 · Cited by 695
“Mechanisms underlying the anxiolytic effects of 5-HT1AR activation are complex, varying between both brain region, and pre- versus postsynaptic locus, and are not fully established [56].”
BackgroundSerotonin and brain function: a tale of two receptors
Carhart-Harris, R., & Nutt, D. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881117725915 · Cited by 739
“…may inform on the function of brain serotonin, one may think of enhancing 5-HT2AR signalling as analogous to increasing the temperature (or excitability) of the brain; indeed, the excitatory effect of 5-HT2AR signalling has long been recognised (Aghajanian and Marek, 1999; Celada et al., 2013b).”
BackgroundResultInfluentialPharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options
Garakani, A., Murrough, J. W., Freire, R. C., Thom, R. P., Larkin, K., Buono, F. D., & Iosifescu, D. V. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.595584 · Cited by 440
“As noted above, buspirone has been FDA-approved for the treatment of anxiety, which led to the consideration of other azapirones (100).”
BackgroundThe Roles of Serotonin in Neuropsychiatric Disorders
Pourhamzeh, M., Moravej, F. G., Arabi, M., Shahriari, E., Mehrabi, S., Ward, R., Ahadi, R., & Joghataei, M. T. (2022) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-021-01064-9 · Cited by 366
Structure and function of serotonin G protein-coupled receptors
McCorvy, J. D., & Roth, B. L. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.01.009 · Cited by 372
“The 5HT1A receptor has been implicated in anxiety, and as mentioned, novel anti-depressants and antipsychotics have begun to incorporate partial 5-HT1A agonist activity to enhance their efficacy in such diseases (Celada et al., 2013).”
Influential
Metadata
- Authors
- Celada, P., Bortolozzi, A., & Artigas, F.
- Affiliations
- Consejo Superior de Investigaciones Científicas (ES)
- Corresponding author
- Artigas, Francesc
- Venue
- CNS Drugs
- Published
- 2013-06-12
- Volume
- 27
- Issue
- 9
- Pages
- 703-716
- ISSN
- 1172-7047 (ISSN-L)
- 1179-1934
- OpenAlex
- W2054695075
- Cited by
- 323
- References
- 205
- Citations by year
- 2026: 13 · 2025: 25 · 2024: 22 · 2023: 26 · 2022: 15 · 2021: 28 · 2020: 22 · 2019: 23 · 2018: 26 · 2017: 31 · 2016: 26 · 2015: 34 · 2014: 25 · 2013: 7
- FWCI
- 15.38
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- CNS Drugs (publishedVersion)
- PubMed (publishedVersion)
- DIGITAL.CSIC (Spanish National Research Council (CSIC)) (submittedVersion)
- Funders
- Les Laboratories Pierre Fabre
- Generalitat de Catalunya
- Centro de Investigación Biomédica en Red de Salud Mental
- Instituto de Salud Carlos III
- European Regional Development Fund
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- 5-HT1A receptor, postsynaptic 5-HT1A receptors, major depressive disorder, anxiety disorders, schizophrenia, antidepressant mechanism, serotonin transporter, selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, pindolol, vilazodone, vortioxetine, partial agonists, negative feedback, brain development, siRNA
- MeSH terms
- Animals, Mental Disorders, Humans, Receptors, Serotonin, 5-HT1, Serotonin 5-HT1 Receptor Agonists, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.